A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
This phase II trial was designed to verify that subcutaneous (SC) administration of Amifostine (Ethyol) protects against radiation therapy (RT)-induced xerostomia and ameliorates amifostine-related side effects (including nausea, vomiting, and hypotension). Patients receiving amifostine SC plus RT had a 56% incidence of acute xerostomia, comparable with previous phase III data with intravenous administration of amifostine. There was good tolerability, with cutaneous toxicity as the most significant side effect. These data suggest that amifostine SC provided comparable protection against RT-induced acute xerostomia as amifostine intravenously.
Anné
Pramila Rani
PR
Kimmel Cancer Center of Jefferson Medical College, Philadelphia, PA, USA.
Curran
Walter J
WJ
D000208:Acute Disease; D004999:Amifostine / Q000008:administration & dosage* / Q000009:adverse effects; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D007279:Injections, Subcutaneous; D009325:Nausea / Q000517:prevention & control; D011832:Radiation Injuries / Q000517:prevention & control; D011837:Radiation-Protective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D011879:Radiotherapy Dosage; D014987:Xerostomia / Q000209:etiology / Q000517:prevention & control
D011837:Radiation-Protective Agents; D004999:Amifostine